Luciano Wannesson

1.6k total citations
31 papers, 440 citations indexed

About

Luciano Wannesson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Luciano Wannesson has authored 31 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Luciano Wannesson's work include Lung Cancer Treatments and Mutations (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (6 papers). Luciano Wannesson is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lymphoma Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (6 papers). Luciano Wannesson collaborates with scholars based in Switzerland, United States and Italy. Luciano Wannesson's co-authors include Emanuele Zucca, Michele Ghielmini, Luca Mazzucchelli, Milo Frattini, Patrizia Froesch, Tony Panzarella, Vittoria Martin, Franco Cavalli, Armand Keating and Diego Cortinovis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Luciano Wannesson

31 papers receiving 434 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luciano Wannesson Switzerland 14 235 174 112 101 67 31 440
Dae Ro Choi South Korea 14 167 0.7× 157 0.9× 98 0.9× 94 0.9× 73 1.1× 43 468
Jacques Olivier Bay France 12 201 0.9× 203 1.2× 116 1.0× 77 0.8× 80 1.2× 30 474
D. Jaeger Germany 10 370 1.6× 115 0.7× 97 0.9× 59 0.6× 88 1.3× 18 566
Jeffrey B. Hargis United States 10 279 1.2× 84 0.5× 175 1.6× 67 0.7× 46 0.7× 16 476
Keishi Naruse Japan 12 106 0.5× 167 1.0× 125 1.1× 71 0.7× 44 0.7× 58 420
J. Mazurka Canada 10 120 0.5× 85 0.5× 167 1.5× 68 0.7× 45 0.7× 15 488
M.-C. Pujazon France 9 110 0.5× 109 0.6× 102 0.9× 50 0.5× 171 2.6× 22 392
Zijun Zhen China 12 155 0.7× 60 0.3× 103 0.9× 65 0.6× 44 0.7× 62 389
JoAnn C. Kelly United States 11 192 0.8× 105 0.6× 76 0.7× 102 1.0× 37 0.6× 17 466
Rosanna Mancari Italy 16 194 0.8× 98 0.6× 103 0.9× 52 0.5× 49 0.7× 33 619

Countries citing papers authored by Luciano Wannesson

Since Specialization
Citations

This map shows the geographic impact of Luciano Wannesson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luciano Wannesson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luciano Wannesson more than expected).

Fields of papers citing papers by Luciano Wannesson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luciano Wannesson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luciano Wannesson. The network helps show where Luciano Wannesson may publish in the future.

Co-authorship network of co-authors of Luciano Wannesson

This figure shows the co-authorship network connecting the top 25 collaborators of Luciano Wannesson. A scholar is included among the top collaborators of Luciano Wannesson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luciano Wannesson. Luciano Wannesson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schmid, Sabine, Sämi Schär, Oliver Gautschi, et al.. (2023). Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung Cancer. 187. 107427–107427. 9 indexed citations
2.
Wannesson, Luciano, et al.. (2022). Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. Cancers. 14(17). 4103–4103. 15 indexed citations
3.
Subbiah, Vivek, Luis Paz‐Ares, Benjamin Besse, et al.. (2021). MO01.10 Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge. Journal of Thoracic Oncology. 16(1). S19–S20. 1 indexed citations
4.
Ghielmini, Michele, et al.. (2020). Risk factors for renal toxicity after inpatient cisplatin administration. BMC Pharmacology and Toxicology. 21(1). 19–19. 27 indexed citations
5.
Mark, Michael, Patrizia Froesch, E.I. Eboulet, et al.. (2020). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. Cancer Immunology Immunotherapy. 70(5). 1255–1262. 11 indexed citations
6.
Martin, Vittoria, et al.. (2020). Functional and clinical significance of ROR1 in lung adenocarcinoma. BMC Cancer. 20(1). 1085–1085. 14 indexed citations
7.
Baumgartner, Annic, Mario Bargetzi, Annika Bargetzi, et al.. (2016). Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. Nutrition. 35. 43–50. 37 indexed citations
8.
Wannesson, Luciano, Dominik Berthold, Richard Cathomas, et al.. (2016). Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. Clinical Genitourinary Cancer. 15(3). e315–e323. 5 indexed citations
9.
Sahnane, Nora, Milo Frattini, Barbara Bernasconi, et al.. (2015). EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. Clinical Lung Cancer. 17(1). 56–61. 28 indexed citations
10.
Cortinovis, Diego, et al.. (2014). MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises. Current Pharmaceutical Design. 20(24). 3982–3990. 31 indexed citations
11.
Karachaliou, Niki, Carlota Costa, Ana Giménez‐Capitán, et al.. (2013). BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations. Journal of Thoracic Oncology. 8(3). 295–300. 15 indexed citations
12.
Wannesson, Luciano, Mario Bargetzi, Anne Cairoli, et al.. (2012). Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leukemia & lymphoma. 54(1). 36–40. 4 indexed citations
13.
14.
Conconi, Annarita, Maddalena Motta, Francesco Bertoni, et al.. (2010). Patterns of survival of follicular lymphomas at a single institution through three decades. Leukemia & lymphoma. 51(6). 1028–1034. 24 indexed citations
15.
Wannesson, Luciano, et al.. (2009). Peliosis Hepatis in Cancer Patients Mimicking Infection and Metastases. Oncology Research and Treatment. 32(1-2). 54–56. 5 indexed citations
16.
Ponti, Giovanni, Lorena Losi, Giovanni Pellacani, et al.. (2008). Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer. British Journal of Dermatology. 159(1). 162–168. 19 indexed citations
17.
Wannesson, Luciano, et al.. (2007). Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Annals of Oncology. 18(4). 623–632. 22 indexed citations
18.
Zucca, Emanuele, Annarita Conconi, Maddalena Motta, et al.. (2007). 6005 ORAL Are we changing the survival of follicular lymphomas? Patterns of outcome in the patients treated at the Oncology Institute of Southern Switzerland from 1979 to 2006. European Journal of Cancer Supplements. 5(4). 346–347. 1 indexed citations
19.
Wannesson, Luciano, Franco Cavalli, & Emanuele Zucca. (2005). Primary Pulmonary Lymphoma: Current Status. Clinical Lymphoma & Myeloma. 6(3). 220–227. 13 indexed citations
20.
Wannesson, Luciano & Michele Ghielmini. (2003). Overview of Antibody Therapy in B-Cell Non-Hodgkin's Lymphoma. Clinical Lymphoma. 4. S5–S12. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dae Ro Choi Breakdown of academic impact, for papers by Jacques Olivier Bay Breakdown of academic impact, for papers by D. Jaeger Breakdown of academic impact, for papers by Jeffrey B. Hargis Breakdown of academic impact, for papers by Keishi Naruse Breakdown of academic impact, for papers by J. Mazurka Breakdown of academic impact, for papers by M.-C. Pujazon Breakdown of academic impact, for papers by Zijun Zhen Breakdown of academic impact, for papers by JoAnn C. Kelly Breakdown of academic impact, for papers by Rosanna Mancari
Rankless by CCL
2026